



Alpha Cognition Inc.
CSE: ACOG
c/o 1200 – 750 West Pender Street
Vancouver, BC, V6C 2T8
www.alphacognition.com
info@alphacognition.com

NEWS RELEASE

Alpha Cognition Announces Resale Registration Statement Declared Effective

VANCOUVER, B.C., June 7, 2024. **Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF)** (“**Alpha Cognition**”, or the “**Company**”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce that the U.S. Securities and Exchange Commission (SEC) has declared effective the Company’s previously filed resale registration statement on Form S-1 to register the resale of common shares issued pursuant to the Company’s private placement transactions, which closed on August 31, October 16, November 8, and December 22 of 2023 and January 19, 2024. The registration statement was filed pursuant to registration rights granted by the Company in connection with the private placements to the selling shareholders named in the registration statement. The registration statement on Form S-1 became effective as of June 7, 2024.

As a result of the effectiveness of the Registration Statement, the Company is a reporting issuer under Section 15(d) of the United States Securities Exchange Act of 1934, as amended, including the filing of financial statements in accordance with U.S. Generally Accepted Accounting Principles. Such reports will be available at the SEC website and on the Company’s website. The Company will file ongoing reports with the SEC in accordance with applicable US federal securities laws.

The Company is not selling any securities under the Registration Statement. The Company will not receive any proceeds from any sale of securities by the selling securityholders pursuant to the Registration Statement.

Copies of the registration statement and the prospectus contained therein may be obtained from the company by request made to Alpha Cognition care/of 1200, 750 West Pender St., Vancouver, B.C., V6C 2T8, or by e-mail at info@alphacognition.com, or by visiting EDGAR, or www.sec.gov.

This news release does not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.



Alpha Cognition Inc.
CSE: ACOG
c/o 1200 – 750 West Pender Street
Vancouver, BC, V6C 2T8
www.alphacognition.com
info@alphacognition.com

About Alpha Cognition Inc.

Alpha Cognition Inc. is a pre-commercial, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease, for which there are limited or no treatment options. The Company is focused on the development of ALPHA-1062 for the treatment of mild-to-moderate Alzheimer’s disease following the recent New Drug Application submission and acceptance by the U.S. Food and Drug Administration.

ALPHA-1062, is a patented new innovative product being developed as a next generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ALPHA-1062’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is in development in combination with memantine to treat moderate to severe Alzheimer’s disease, in development with sublingual formulation for patients suffering from dysphagia and is being out-licensed to study an intranasal formulation for cognitive impairment with mTBI (otherwise known as concussion).

For further information:

Michael McFadden, CEO

Tel: 1-858-344-4375

info@alphacognition.com

<https://www.alphacognition.com/>

Neither Canadian Securities Exchange or the OTC Markets Group, accepts responsibility for the adequacy or accuracy of this release.

Forward-looking Statements

This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward-looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements may include statements regarding the TBI out-licensing plan and associated financing, the availability of



Alpha Cognition Inc.
CSE: ACOG
c/o 1200 – 750 West Pender Street
Vancouver, BC, V6C 2T8
www.alphacognition.com
info@alphacognition.com

funding pursuant to financings, the Company's business strategy, market size, potential growth opportunities, capital requirements, clinical development activities, the timing and results of clinical trials, regulatory submissions, potential regulatory approval and commercialization of the Company's products. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward-looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward-looking statements for any reason, even if new information becomes available in the future.